Benzinga | Apr 28, 2021 08:06AM EDT

Inozyme Pharma, Researchers From Thomas Jefferson University To Present Preclinical Data Suggesting Utility Of INZ-701 As Potential Treatment For ABCC6 Deficiency At 2 Upcoming Medical Conferences

Inozyme Pharma, Inc. (NASDAQ:INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the potential treatment for ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE) will be presented at the following upcoming medical conferences:



Conference: Society for Investigative Dermatology (SID) 2021 Virtual Meeting

Title: INZ-701 prevents ectopic mineralization in an Abcc6-/- mouse model of pseudoxanthoma elasticum

Presenter: Joely D. Jacobs, Research Assistant, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University

Session: Interactive Poster/Exhibitor Session I

Date and Time: Wednesday, May 5, 2021 from 2:30-4:00 p.m. E.T.

Conference: European Calcified Tissue Society (ECTS) 2021 Digital Congress

Title: INZ-701, a recombinant ENPP1-Fc protein, prevents ectopic mineralization in a mouse model of Pseudoxanthoma Elasticum

Presenter: Zhiliang Cheng, Ph.D., Vice President, Research at Inozyme Pharma

Session: Plenary Oral Presentations 1: Genetics & Bone

Date and Time: Friday, May 7, 2021 from 10:30-11:30 a.m. C.E.T.

About Inozyme Pharma

Inozyme Pharma (NASDAQ:INZY) is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.